default author photo

Chizobam Obi

University of Texas at Houston - Department of Lymphoma and Myeloma

Houston, TX

United States

  • University of Texas at Houston - Department of Lymphoma and Myeloma

SCHOLARLY PAPERS

2

DOWNLOADS

75

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial

Number of pages: 42 Posted: 08 Apr 2024
Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers and Loretta J. Nastoupil
University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 75 (837,727)

Abstract:

Loading...

Follicular Lymphoma, B-Cell Lymphoma, Lenalidomide, Therapeutic Use, Obinutuzumab, Antineoplastic Agents, Immunological

2.

Safety and Activity of Pembrolizumab in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Posted: 01 Mar 2021
Loretta J. Nastoupil, Collin K. Chin, Jason R. Westin, Nathan H. Fowler, Felipe Samaniego, JinJing Cao, Xiaoyun Chen, Man Chun John Ma, Zhiqiang Wang, Fuliang Chu, Ly Dsouza, Chizobam Obi, Jennifer Mims, Lei Feng, Shouhao Zhou, Michael Green, R. Eric Davis and Sattva S. Neelapu
University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma

Abstract:

Loading...